Luo Haoxuan, Chen Yan, Sun Baoguo, Xiang Ting, Zhang Shijun
Department of Chinese Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong, P. R. China.
Department of Chinese Medicine, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, Guangdong, P. R. China.
Afr J Tradit Complement Altern Med. 2016 Nov 23;14(1):165-173. doi: 10.21010/ajtcam.v14i1.18. eCollection 2017.
Spleen-deficiency syndrome (SDS) in Traditional Chinese Medicine (TCM) played pivotal roles on the development of hepatocellular carcinoma (HCC). This study was performed to establish and evaluate HCC model in mice with SDS in TCM.
A total of 90 C57BL/6 mice were randomized in six groups (n=15 for each group): A, Control group; B, SDS group; C, orthotopic HCC (OHCC) group; D, OHCC based on SDS (SDS-OHCC) group; E, Drug-induced HCC (DHCC) group; F, DHCC based on SDS (SDS-DHCC) group. The SDS model were established by subcutaneous injection of reserpine, followed by the OHCC or DHCC model establishment. The SDS scores, tumor formation rate and survival time were recorded and calculated, as well as the histochemical stain was performed.
The SDS scores of mice in Group B, D, F were 17.57±4.86 (P<0.05 vs. Group A), 18.13±4.53 (P<0.05 vs. Group A and C) and 23.32±4.94 (P<0.05 vs. Group A and E) respectively. The tumor formation rate of mice in Group C, D, E and F were 73.33%, 100%, 60% and 80% respectively. The survival time of mice in Group C, D, E and F were 26.42±5.27, 17.33±4.76 (P<0.05 vs. Group C), 35.77±6.12 and 22.61±5.05 (P<0.05 vs. Group E) respectively.
The SDS-oriented HCC mice models were simple and easily-operated models for further studies on SDS oriented tumor. Meanwhile, SDS was a pivotal factor for low outcome of hepatic tumor. HCC, Hepatocellular carcinoma; OHCC, Orthotopic hepatocellular carcinoma; DHCC, Drug-induced hepatocellular carcinoma; SDS, Spleen-deficiency syndrome; TCM, Traditional Chinese Medicine; SPF, Specific pathogen-free; DEN, Diethylnitrosamine; CCl4, Carbon tetrachloride; HE, Hematoxylin-eosin; IACUC, Institutional Animal Care and Use Committee.
中医的脾虚证在肝细胞癌（HCC）的发生发展中起关键作用。本研究旨在建立并评估中医脾虚证小鼠肝癌模型。
将90只C57BL/6小鼠随机分为6组（每组n = 15）：A组为对照组；B组为脾虚证组；C组为原位肝癌（OHCC）组；D组为基于脾虚证的原位肝癌（SDS - OHCC）组；E组为药物诱导性肝癌（DHCC）组；F组为基于脾虚证的药物诱导性肝癌（SDS - DHCC）组。通过皮下注射利血平建立脾虚证模型，随后建立OHCC或DHCC模型。记录并计算脾虚证评分、肿瘤形成率和生存时间，并进行组织化学染色。
B组、D组、F组小鼠的脾虚证评分分别为17.57±4.86（与A组相比，P<0.05）、18.13±4.53（与A组和C组相比，P<0.05）和23.32±4.94（与A组和E组相比，P<0.05）。C组、D组、E组和F组小鼠的肿瘤形成率分别为73.33%、100%、60%和80%。C组、D组、E组和F组小鼠的生存时间分别为26.42±5.27、17.33±4.76（与C组相比，P<0.05）、35.77±6.12和22.61±5.05（与E组相比，P<0.05）。
以脾虚证为导向的肝癌小鼠模型是用于脾虚证导向肿瘤进一步研究的简单易操作模型。同时，脾虚证是肝脏肿瘤预后不良的关键因素。HCC：肝细胞癌；OHCC：原位肝细胞癌；DHCC：药物诱导性肝细胞癌；SDS：脾虚证；TCM：中医；SPF：无特定病原体；DEN：二乙基亚硝胺；CCl4：四氯化碳；HE：苏木精 - 伊红；IACUC：机构动物护理和使用委员会
